Skip to main content
Erschienen in: Clinical Drug Investigation 8/2018

01.08.2018 | Original Research Article

The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea

verfasst von: Sung-Hyun Hong, Jae-Yeon Lee, Sun-Kyeong Park, Jin Hyun Nam, Hyun Jin Song, Sun-Young Park, Eui-Kyung Lee

Erschienen in: Clinical Drug Investigation | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Utility provides a preference for specific health state in economic evaluation, and they obtained from general population could be useful in respect of societal resource allocation. We aimed to investigate the utilities of health states for heart failure (HF), a major and growing public health problem, related to hospitalization and adverse drug effects by interrogating the general Korean population.

Methods

Five health states for patients with HF were developed based on literature reviews: stable chronic heart failure (SCHF), hospitalization, SCHF + cough, SCHF + hypotension, and SCHF + hyperkalemia. We selected 100 individuals from the general population through quota sampling by age, sex, and region, and conducted face-to-face interviews. We measured utilities for 5 hypothetical health states of HF using both time trade-off (TTO) and EuroQol-5 dimensions-5 levels (EQ-5D-5L). Repeated-measures analysis of variance compared the utilities between all health states for each instrument. To identify the factors affecting the utility, a linear mixed model (LMM) analysis was performed.

Results

The mean utility value for SCHF, SCHF + cough, SCHF + hypotension, SCHF + hyperkalemia, and hospitalization was calculated as 0.815, 0.732, 0.646, 0.548, and 0.360, respectively, by using TTO. The respective values using EQ-5D-5L were 0.871, 0.793, 0.710, 0.589, and 0.215. The utilities for HF significantly differed between all health states in each instrument (p < 0.001). In LMM analysis, hospitalization had a significantly negative effect on the utilities of both instruments.

Conclusions

The utilities decreased in order of SCHF, SCHF + cough, SCHF + hypotension, SCHF + hyperkalemia, and hospitalization. These results can be useful for decision making in resource allocation for HF interventions.
Literatur
3.
Zurück zum Zitat Bennett SJ, Cordes DK, Westmoreland G, Castro R, Donnelly E. Self-care strategies for symptom management in patients with chronic heart failure. Nurs Res. 2000;49(3):139–45.CrossRefPubMed Bennett SJ, Cordes DK, Westmoreland G, Castro R, Donnelly E. Self-care strategies for symptom management in patients with chronic heart failure. Nurs Res. 2000;49(3):139–45.CrossRefPubMed
4.
Zurück zum Zitat Morgan K, McGee H, Shelley E. Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review. Eur J Cardiovasc Prev Rehabil. 2007;14(5):589–607.CrossRefPubMed Morgan K, McGee H, Shelley E. Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review. Eur J Cardiovasc Prev Rehabil. 2007;14(5):589–607.CrossRefPubMed
5.
Zurück zum Zitat Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2005;4(3):198–206.CrossRefPubMed Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2005;4(3):198–206.CrossRefPubMed
6.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.CrossRefPubMed McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.CrossRefPubMed
7.
Zurück zum Zitat McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.CrossRefPubMed McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.CrossRefPubMed
8.
Zurück zum Zitat Brignall K, Jayaraman B, Birring SS. Quality of life and psychosocial aspects of cough. Lung. 2008;186(Suppl 1):S55–8.CrossRefPubMed Brignall K, Jayaraman B, Birring SS. Quality of life and psychosocial aspects of cough. Lung. 2008;186(Suppl 1):S55–8.CrossRefPubMed
9.
Zurück zum Zitat Thompson A. Hypotension: issues and management. PJ Online. 2011;1–4. Thompson A. Hypotension: issues and management. PJ Online. 2011;1–4.
10.
Zurück zum Zitat Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67(10):1289–98.CrossRefPubMed Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67(10):1289–98.CrossRefPubMed
11.
Zurück zum Zitat Testa MA, Simonson DC. Assesment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835–40.CrossRefPubMed Testa MA, Simonson DC. Assesment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835–40.CrossRefPubMed
12.
Zurück zum Zitat Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593–603.CrossRefPubMed Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593–603.CrossRefPubMed
13.
Zurück zum Zitat Drummond MF, O’Brien B, Stodart G, Torrance GW. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 137–88. Drummond MF, O’Brien B, Stodart G, Torrance GW. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 137–88.
14.
Zurück zum Zitat Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21.CrossRefPubMed Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21.CrossRefPubMed
15.
Zurück zum Zitat Bae S, Lee S, Bae EY, Jang S. Korean guidelines for pharmacoeconomic evaluation (second and updated version): consensus and compromise. Pharmacoeconomics. 2013;31(4):257–67.CrossRefPubMed Bae S, Lee S, Bae EY, Jang S. Korean guidelines for pharmacoeconomic evaluation (second and updated version): consensus and compromise. Pharmacoeconomics. 2013;31(4):257–67.CrossRefPubMed
16.
Zurück zum Zitat Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. 2nd ed. Oxford: Oxford University Press; 2016. p. 112–6.CrossRef Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. 2nd ed. Oxford: Oxford University Press; 2016. p. 112–6.CrossRef
17.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.CrossRefPubMed
18.
Zurück zum Zitat Sarwar CMS, Papadimitriou L, Pitt B, Piña I, Zannad F, Anker SD, et al. Hyperkalemia in heart failure. J Am Coll Cardiol. 2016;68(14):1575–89.CrossRefPubMed Sarwar CMS, Papadimitriou L, Pitt B, Piña I, Zannad F, Anker SD, et al. Hyperkalemia in heart failure. J Am Coll Cardiol. 2016;68(14):1575–89.CrossRefPubMed
19.
Zurück zum Zitat Parkerson GR Jr, Connis RT, Broadhead WE, Patrick DL, Taylor TR, Tse CK. Disease-specific versus generic measurement of health-related quality of life in insulin-dependent diabetic patients. Med Care. 1993;31(7):629–39.CrossRefPubMed Parkerson GR Jr, Connis RT, Broadhead WE, Patrick DL, Taylor TR, Tse CK. Disease-specific versus generic measurement of health-related quality of life in insulin-dependent diabetic patients. Med Care. 1993;31(7):629–39.CrossRefPubMed
20.
Zurück zum Zitat Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.CrossRefPubMed Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.CrossRefPubMed
21.
Zurück zum Zitat Kim SH, Jo MW, Ahn J, Shin S, Ock M, Park J, et al. The valuation of EQ-5D-5L health states in Korea. Value Health. 2014;17(7):A753.CrossRefPubMed Kim SH, Jo MW, Ahn J, Shin S, Ock M, Park J, et al. The valuation of EQ-5D-5L health states in Korea. Value Health. 2014;17(7):A753.CrossRefPubMed
22.
Zurück zum Zitat Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013;14(Suppl 1):S53–64.CrossRefPubMed Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013;14(Suppl 1):S53–64.CrossRefPubMed
24.
Zurück zum Zitat Kim S-H, Ahn J, Ock M, Shin S, Park J, Luo N, et al. The EQ-5D-5L valuation study in Korea. Qual Life Res. 2016;25(7):1845–52.CrossRefPubMed Kim S-H, Ahn J, Ock M, Shin S, Park J, Luo N, et al. The EQ-5D-5L valuation study in Korea. Qual Life Res. 2016;25(7):1845–52.CrossRefPubMed
25.
Zurück zum Zitat Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail. 2012;14(12):1401–9.CrossRefPubMed Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail. 2012;14(12):1401–9.CrossRefPubMed
26.
Zurück zum Zitat Sztramko R, Chau V, Wong R. Adverse drug events and associated factors in heart failure therapy among the very elderly. Can Geriatr J. 2011;14(4):79–92.CrossRefPubMedPubMedCentral Sztramko R, Chau V, Wong R. Adverse drug events and associated factors in heart failure therapy among the very elderly. Can Geriatr J. 2011;14(4):79–92.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert J-C, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28(1):42–51.CrossRefPubMed Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert J-C, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28(1):42–51.CrossRefPubMed
28.
Zurück zum Zitat Griffiths A, Paracha N, Davies A, Branscombe N, Cowie M. Sculpher M The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart. 2014;100:1031–6.CrossRefPubMedPubMedCentral Griffiths A, Paracha N, Davies A, Branscombe N, Cowie M. Sculpher M The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart. 2014;100:1031–6.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol. 2016;74(10):1037–147.CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol. 2016;74(10):1037–147.CrossRefPubMed
30.
Zurück zum Zitat Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed
31.
Zurück zum Zitat Nafees B, Cowie M, Patel C, Deschaseaux C, Brazier J, Lloyd A. Health state utilities in chronic heart failure in the UK. Value Health. 2014;17(7):A493.CrossRefPubMed Nafees B, Cowie M, Patel C, Deschaseaux C, Brazier J, Lloyd A. Health state utilities in chronic heart failure in the UK. Value Health. 2014;17(7):A493.CrossRefPubMed
32.
Zurück zum Zitat Drummond M, Brixner D, Gold M, Kind P, McGuire A, Nord E, Group CD. Toward a consensus on the QALY. Value Health. 2009;12(Suppl 1):S31–5.CrossRefPubMed Drummond M, Brixner D, Gold M, Kind P, McGuire A, Nord E, Group CD. Toward a consensus on the QALY. Value Health. 2009;12(Suppl 1):S31–5.CrossRefPubMed
33.
Zurück zum Zitat Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5–9.CrossRefPubMed Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5–9.CrossRefPubMed
34.
Zurück zum Zitat Eisele M, Blozik E, Stork S, Trader JM, Herrmann-Lingen C, Scherer M. Recognition of depression and anxiety and their association with quality of life, hospitalization and mortality in primary care patients with heart failure - study protocol of a longitudinal observation study. BMC Fam Pract. 2013;14:180.CrossRefPubMedPubMedCentral Eisele M, Blozik E, Stork S, Trader JM, Herrmann-Lingen C, Scherer M. Recognition of depression and anxiety and their association with quality of life, hospitalization and mortality in primary care patients with heart failure - study protocol of a longitudinal observation study. BMC Fam Pract. 2013;14:180.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Konstam V, Moser DK, De Jong MJ. Depression and anxiety in heart failure. J Card Fail. 2005;11(6):455–63.CrossRefPubMed Konstam V, Moser DK, De Jong MJ. Depression and anxiety in heart failure. J Card Fail. 2005;11(6):455–63.CrossRefPubMed
36.
Zurück zum Zitat Polikandrioti M, Goudevenos J, Michalis LK, Koutelekos J, Kyristi H, Tzialas D, et al. Factors associated with depression and anxiety of hospitalized patients with heart failure. Hell J Cardiol. 2015;56(1):26–35. Polikandrioti M, Goudevenos J, Michalis LK, Koutelekos J, Kyristi H, Tzialas D, et al. Factors associated with depression and anxiety of hospitalized patients with heart failure. Hell J Cardiol. 2015;56(1):26–35.
37.
Zurück zum Zitat Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non-small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.CrossRefPubMedPubMedCentral Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non-small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.CrossRefPubMedPubMedCentral
38.
39.
Zurück zum Zitat Luo N, Teng TK, Tay WT, Anand IS, Kraus WE, Liew HB, et al. Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. Am Heart J. 2017;191:75–81.CrossRefPubMedPubMedCentral Luo N, Teng TK, Tay WT, Anand IS, Kraus WE, Liew HB, et al. Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. Am Heart J. 2017;191:75–81.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea
verfasst von
Sung-Hyun Hong
Jae-Yeon Lee
Sun-Kyeong Park
Jin Hyun Nam
Hyun Jin Song
Sun-Young Park
Eui-Kyung Lee
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 8/2018
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-018-0659-8

Weitere Artikel der Ausgabe 8/2018

Clinical Drug Investigation 8/2018 Zur Ausgabe